84 completed, 14 unknown, 9 terminated, 7 recruiting. 126 Phase 2, 22 Phase 1, 13 Phase 3.
Follow Hyperglycemia: new trials by email Literature Review of Hyperglycemia trials Research Report on Hyperglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance | Phase 2 | Withdrawn | University of Arizona | 2030-04-15 | 2025-07-30 | |
| Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults Fish Oil, Corn oil control - Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | Phase 2 | Recruiting | May Faraj, PDt, PhD | 84 | 2026-10-05 | 2026-10-08 |
| Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) controlled-ileal-release nicotinic acid as multiple dose 100 mg/day, controlled-ileal-release nicotinic acid as multiple dose 200 mg/day, controlled-ileal-release nicotinic acid as multiple dose placebo - Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | Phase 2 | Recruiting | University Hospital Schleswig-Holstein | 390 | 2026-03-03 | 2026-09-16 |
| Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes Arginine hydrochloride, Sodium Chloride 0.9% - Diabetes (DM), Diabetic Ketoacidosis | Phase 1 / Phase 2 | Recruiting | David K Carroll | 60 | 2025-12-19 | 2026-02-12 |
| The Role of Islet GLP-1 in the Pathogenesis of Prediabetes Exendin 9-39, Saline - PreDiabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-11-01 | 2025-12-15 |
| Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health Time-restricted eating (TRE) + Standard of Care, Standard of Care - Metabolic Syndrome, Pre-diabetes | Phase 2 | Recruiting | University of California, San Diego | 140 | 2025-10-23 | 2026-02-02 |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin LY3938577, Degludec - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Eli Lilly and Company | 100 | 2025-10-13 | 2026-07-13 |
| Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia Dapagliflozin (DAPA) - Dapagliflozin (Forxiga), Hyperglycaemia | Phase 2 | Active not recruiting | Lauro Fabián Amador Medina | 38 | 2024-12-01 | 2024-12-27 |
| Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level Taiwanese whole grain job's tear (red job's tear), White job's tear - Sarcopenia, Frailty | Phase 2 | Unknown | Taipei Veterans General Hospital, Taiwan | 80 | 2024-06-14 | 2024-07-16 |
| Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients Dapagliflozin 10mg Tab, lifestyle interventions - Prediabetic State, Impaired Fasting Glucose | Phase 2 | Unknown | Yangjin | 120 | 2023-12-20 | 2023-07-25 |
| Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes Dexcom G6 - Hyperglycemia | Phase 1 / Phase 2 | Completed | Ohio State University | 201 | 2023-11-01 | 2026-02-06 |
| Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease Semaglutide Pen Injector, Placebo - Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Active not recruiting | Yale University | 60 | 2023-07-17 | 2026-04-15 |
| Early Versus Conventional Cessation of Hydrocortisone in Septic Shock normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event | Phase 2 | Unknown | Mahidol University | 160 | 2023-07-05 | 2024-04-05 |
| A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test APHD-012, APH-012P - PreDiabetes, Glucose Tolerance Impaired | Phase 2 | Completed | Aphaia Pharma US LLC | 31 | 2023-03-31 | 2024-10-16 |
| Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride) - Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 2 | Completed | Melbourne Health | 68 | 2023-02-13 | 2025-12-24 |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer Evexomostat - HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | SynDevRx, Inc. | 52 | 2022-08-26 | 2026-04-22 |
| Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT Dorzagliatin, Placebo - Glucose Intolerance | Phase 1 / Phase 2 | Unknown | Chinese University of Hong Kong | 20 | 2022-08-01 | 2022-07-25 |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant Alpelisib, Fulvestrant, Metformin XR - Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 2 | 2022-04-06 | 2024-10-09 |
| The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure Empagliflozin 10 MG, Placebo - Obesity, Heart Failure | Phase 2 | Completed | Jacob Moller | 165 | 2021-09-02 | 2025-01-29 |
Showing 20 of 126. Sign in to see all of them.
Glucose Intolerance (74) · Insulin Resistance (27) · Diabetes Mellitus, Type 2 (26) · Diabetes Mellitus (23) · Obesity (20) · Metabolic Syndrome (15) · Prediabetic State (12) · Diabetes Mellitus, Type 1 (9) · Hypertension (9) · Hypoglycemia (9) · Overweight (6) · Heart Failure (5) · Inflammation (4) · Obesity, Abdominal (4)
Nutritional and Metabolic Diseases (126) · Glucose Metabolism Disorders (124) · Metabolic Diseases (123) · Endocrine System Diseases (54) · Pathological Conditions, Signs and Symptoms (42) · Hyperinsulinism (38) · Diabetes Mellitus (32) · Signs and Symptoms (32) · Body Weight (29) · Nutrition Disorders (27) · Overnutrition (27) · Overweight (21) · Cardiovascular Diseases (19) · Vascular Diseases (17)
Metformin (12) · Insulin (8) · Pioglitazone (5) · Sitagliptin Phosphate (5) · Diet (4) · Exenatide (4) · Exercise (4) · Standard of Care (4) · dapagliflozin (4) · Rosiglitazone (3) · Saline Solution (3) · Sodium Chloride (3) · empagliflozin (3) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (2) · Alpelisib (2)
Novartis Pharmaceuticals (4) · University of Guadalajara (4) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Chinese University of Hong Kong (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Genfit (2) · Intermountain Health Care, Inc. (2) · Kathleen Dungan (2) · Marcus Saemann (2) · Mayo Clinic (2) · Milton S. Hershey Medical Center (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Oslo University Hospital (2) · Thomas Jefferson University (2) · University of British Columbia (2)
United States (65) · Canada (11) · Mexico (8) · Germany (6) · Italy (6) · United Kingdom (5) · Norway (4) · Sweden (4) · Austria (3) · China (3) · Denmark (3) · Finland (3) · France (3) · Taiwan (3) · Argentina (2)
Alan H Morris, MD (2) · Francesco Squadrito, MD (2) · Graydon Meneilly, MD (2) · Jeff Bornstein, MD (2) · Kathleen M Dungan, MD (2) · Staffan Lindeberg, MD PhD (2) · Aaron S. Kelly, Ph.D. (1) · Adrian Vella, MD (1) · Aila Rissanen, MD (1) · Alexander Khoruts, MD (1) · Anastassios G Pittas, MD MS (1) · Anchun Hwang, Doctor (1)
PMID 23703580, PMID 32803882, PMID 17583796, PMID 19114908, PMID 19909549, PMID 20332358, PMID 20634174, PMID 20847403, PMID 21118562, PMID 21668924, PMID 21715514, PMID 21741058, PMID 21816979, PMID 21870174, PMID 21901116, PMID 22021788, PMID 22059803, PMID 22076596, PMID 22302620, PMID 22424822, PMID 22547887, PMID 22866170, PMID 22933432, PMID 22985140, PMID 23124047, PMID 23229846, PMID 23514765, PMID 23682163, PMID 23715754, PMID 23733372, PMID 23899172, PMID 24055327, PMID 24369008, PMID 24587337, PMID 24607293, PMID 24933726, PMID 25527657, PMID 25874636, PMID 26210388, PMID 26511012, PMID 26829443, PMID 27194308, PMID 27207552, PMID 27333897, PMID 27737744, PMID 27810310, PMID 28059466, PMID 28945869, PMID 28945992, PMID 29860335
2009 (2), 2016 (1), 2019 (1), K23DK080891 (1), P30AG044271 (1), R01AG050440 (1), R01AG055299 (1), R01AT009484 (1), R01DK076092 (1), R01DK111038 (1), R01HL086667 (1), R01NS050192 (1), R21AT001332 (1), R21AT002374 (1), R21DK081877 (1)